Savara wins $1.9M award for dry-powder tech

Austin-based Savara has picked up a $1.9 million award from the Texas Emerging Technology Fund to back its development of dry-powder versions of respiratory drugs.

The award comes on top of $1.4 million Savara raised in venture capital last year. The company licensed the nanotechnology it uses from the University of Kansas in 2008 and then moved to the Austin Technology Incubator inside the University of Texas. CEO Rob Neville earlier ran a consulting firm and sold a software company back in 2000. The state's technology fund is specifically focused on supporting nanotechnology enterprises.

"Savara's dry-powder technology holds great potential for treating asthma, lung cancer, and other lung-based diseases," said Jack McDonald, chairman of the Central Texas Regional Center of Innovation and Commercialization. "This investment by the ETF will not only help grow our biotech industry in Central Texas but may result in new therapies that save lives."

- read Savara's release
- here's the story from the Austin American-Statesman

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.